

MUPRIN OINTMENT

DESCRIPTION: A white ointment containing 2.0% w/w Mupirocin.

ACTIONS: Mupirocin inhibits bacterial protein synthesis by binding to isoleucyl-transfer RNA synthetase. Due to this particular mode of action and its unique molecular structure, Mupirocin does not show any cross-resistance with other antibiotics. It is mainly active against Gram-positive aerobes, most strains of staphylococci including methicillin-resistant and multiple resistant staphylococcus aureus and streptococci. It is also active against some Gram-negative bacterium.

PHARMACOLOGY: Mupirocin is rapidly inactivated after absorption and its systemic level is undetectable. There is virtually no systemic absorption (< 1.1 nanograms per mL of whole blood) following application to lower arm of normal males with occlusion for 24 hours.

INDICATIONS: Bacterial skin infections.

CONTRAINDICATIONS: Hypersensitivity to Mupirocin, polyethylene glycol or any other constituent in the ointment base.

DRUG INTERACTIONS: Unknown.

ADVERSE EFFECTS: Mupirocin is usually well tolerated but local reactions such as burning, stinging and itching may occur after the application of Mupirocin to the skin. Muprin Ointment has not been reported to cause contact sensitization or photosensitivity reactions. The polyethylene glycol vehicle in Muprin Ointment may irritate broken skin or mucous membranes. Muprin Ointment may cause some unwanted effects. The following side effects may go away during treatment as your body adjusts to the medicine. However, check with your doctor if any of these persist or are bothersome.

Less frequently reported unwanted effects include dry skin; skin burning, itching, pain, rash, redness, stinging or swelling; headache; nausea.

Rarely reported are abdominal pain; dizziness; secondary wound infection; ulcerative stomatitis (sores in mouth or on lips).

PRECAUTIONS/WARNINGS: Not for ophthalmic or intranasal use. Avoid contact with eyes: use with caution if there is evidence of moderate or severe renal impairment. Check with physician or pharmacist if there is no improvement within 3 to 5 days.

Pregnancy: Topical Mupirocin has not been studied in pregnant women. However, this medication has not been shown to cause birth defects or other problems in animal studies.

Breast feeding: It is not known whether topical mupirocin passes into the breast milk. However, this medicine is unlikely to pass into the breast milk in large amounts since very little Mupirocin is absorbed into the mother's body when applied to the skin.

Children: Safety and effectiveness of mupirocin ointment have not been established in children up to 2 months of age.

Elderly adults: No overall difference in safety and efficacy was observed in patients over 65 years of age.

RECOMMENDED DOSAGE: Adult and children: Apply one to three times daily for up to 10 days.

SYMPTOMS AND TREATMENT FOR OVERDOSE AND ANTIDOTE(S): Less frequently reported unwanted effects include: dry skin, skin burning, itching, pain, rash, redness, stinging or swelling, headache and nausea. Rarely reported are: abdominal pain, dizziness, secondary wound infection, ulcerative stomatitis (sores in mouth or on lips).

PACKING: 5g and 15g collapsible aluminium tubes.

STORAGE: Keep container well closed. Protect from strong light. Store below 30°C. Keep out of reach of children.

RECOMMENDED SHELF-LIFE: 3 years

Manufactured by:

HOE Pharmaceuticals Sdn. Bhd.

Lot 10 Jalan Sultan Mohd. 6, Bandar Sultan Suleiman,
42000 Port Klang, MALAYSIA.